Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity, Safety, and Antibody Persistence of Different Immunization Strategies Against Japanese Encephalitis
NCT06825312Phase 4Active, not recruiting
- Sponsor
- Liaoning Chengda Biotechnology Co., Ltd.
- Start
- Nov 2023
- Primary completion
- Dec 2030
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Japanese encephalitis vaccine and japanese encephalitis vaccine sa14-14-2 in Japanese encephalitis (JE) (6 arms), sponsored by Liaoning Chengda Biotechnology Co., Ltd. Primary endpoint: Percentage of Participants Testing Seropositive for Japanese Encephalitis Neutralizing Antibodies. Started Nov 2023; status: active, not recruiting.
02
Drugs
Japanese encephalitis vaccinejapanese encephalitis vaccine sa14-14-2
03
Conditions
Japanese encephalitis (JE)
Beyond the preview
Go deeper on NCT06825312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06825312.